ABSTRACT
With survival rates for childhood cancers now being overall in the region of 75 per cent,1 the long-term consequences of these diseases and their treatments need to be documented so that appropriate strategies for monitoring patients into adult life can be devised, and rapid treatment offered when appropriate. Parallels can be drawn with recipients of organ allografts whose ongoing immunosuppressed state predisposes them both to longterm infective and malignant complications.2
